Evaluation of Asymmetric Dimethylarginine, Malondialdehyde, and Vitamin Levels of Borderline Personality Disorder Patients With and Without Self-Mutilation

키워드

참고문헌 (33)

1. MacDowella KS, "Inflammatory and antioxidant pathway dysfunction in borderline personality disorder", Psychiatry Res, 284, pp.112782~ (2020)
2. American Psychiatric Association, "Diagnostic and statistical manual of mental disorders" (2013), American Psychiatric Publishing
3. Zimmerman M, "Axis I diagnostic comorbidity and borderline personality disorder", Compr Psychiatry, 40, pp.245~252 (1999)
4. Anderson G, "Pathoetiology and pathophysiology of borderline personality : role of prenatal factors, gut microbiome, mu-and kappa-opioid receptors in amygdala-PFC interactions", Prog Neuropsychopharmacol Biol Psychiatry, 98, pp.109782~ (2020)
5. Lee RJ, "Narcissistic and borderline personality disorders : relationship with oxidative stress", J Pers Disord, 34, pp.6~24 (2020)
6. Mopuru R, "Cycloxoygenase-2 inhibitors: a novel treatment option for borderline personality disorder?", Indian J Psychol Med (2023)[DOI]
7. Saccora LF, "Inflammation, anxiety, and stress in bipolar disorder and borderline personality disorder : a narrative review", Neurosci Biobehav Rev, 127, pp.184~192 (2021)
8. Sher L, "Gender differences and similarities in aggression, suicidal behaviour, and psychiatric comorbidity in borderline personality disorder", Acta Psychiatr Scand, 139, pp.145~153 (2019)
9. Minutolo G, "Nitric oxide in patients with schizophrenia : the relationship with the severity of illness and the antipsychotic treatment", Expert Opin Pharmacother, 13, pp.1989~1997 (2012)
10. Ustundag MF, "Nitric oxide, asymmetric dimethylarginine, symmetric dimethylarginine and L-arginine levels in psychotic exacerbation of schizophrenia and bipolar disorder manic episode", Saudi Med J, 41, pp.38~45 (2020)
11. Canpolat S, "Relationship of asymmetrical dimethylarginine, nitric oxide, and sustained attention during attack in patients with major depressive disorder", Sci World J, 2014, pp.624395~ (2014)
12. Aydemir Ö, "Oxidative stress markers, cognitive functions, and psychosocial functioning in bipolar disorder : an empirical cross-sectional study", Braz J Psychiatry, 36, pp.293~297 (2014)
13. Sorias S, "DSM-III-R structured clinical interview Turkish version SCID-II personality disorders form" (1990), Ege University Press
14. Beck AT, "An inventory for measuring clinical anxiety : psychometric properties", J Consult Clin Psychol, 56, pp.893~897 (1988)
15. Hisli N, "A Study on the Validity of the Beck Depression Inventory", Turk Psikol Derg, 22, pp.118~126 (1988)
16. Jorgensen A, "Asymmetric dimethylarginine in somatically healthy schizophrenia patients treated with atypical antipsychotics : a case-control study", BMC Psychiatry, 15, pp.67~ (2015)
17. Alderton WK, "Nitric oxide synthases : structure, function and inhibition", Biochem J, 357, pp.593~615 (2001)
18. Rujescu D, "NOS-I and-III gene variants are differentially associated with facets of suicidal behavior and aggression-related traits", Am J Med Genet B Neuropsychiatr Genet, 147B, pp.42~48 (2008)
19. Zhoua QG, "Neuronal nitric oxide synthase and affective disorders", IBRO Rep, 5, pp.116~132 (2018)
20. Köse SS, "Personality disorders diagnosis, causes, and treatments", Demiroglu Sci Univ Florence Nightingale J Transplant, 5, pp.22~31 (2020)
21. Reif A, "Influence of functional variant of neuronal nitric oxide synthase on impulsive behaviors in humans", Arch Gen Psychiatry, 66, pp.41~50 (2009)
22. Reif A, "A functional NOS1 promoter polymorphism interacts with adverse environment on functional and dysfunctional impulsivity", Psychopharmacology(Berl), 214, pp.239~248 (2011)
23. Eli R, "A chronopharmacological diagnostic test and treatment for bipolar disorder and depression : nitric oxide release during sleep causes it to become depressogenic in a subset of patients", Med Hypotheses, 66, pp.72~75 (2006)
24. Kielstein H, "Role of the endogenous nitric oxide inhibitor asymmetric dimethylarginine(ADMA)and brain-derived neurotrophic factor(BDNF)in depression and behavioural changes : clinical and preclinical data in chronic kidney disease", Nephrol Dial Transplant, 30, pp.1699~1705 (2015)
25. Forte ARCC, "Oxidative stress and inflammatory process in borderline personality disorder(BPD) : a narrative review", Braz J Med Biol Res, 56, pp.e12484~ (2023)
26. Manosso LM, "Vitamin E for the management of major depressive disorder : possible role of the anti-inflammatory and antioxidant systems", Nutr Neurosci, 25, pp.1310~1324 (2020)
27. Wójcicka G, "The paraoxonase 1 (PON1), platelet-activating factor acetylohydrolase (PAF-AH) and dimethylarginine dimethylaminohydrolase (DDAH) activity in the metformin treated normal and diabetic rats", Eur J Pharmacol, 789, pp.187~194 (2016)
28. Hurşitoğlu O, "Diagnostic performance of increased malondialdehyde level and oxidative stress in patients with schizophrenia", Noro Psikiyatr Ars, 58, pp.184~188 (2021)
29. Sydow K, "ADMA and oxidative stress", Atheroscler Suppl, 4, pp.41~51 (2003)
30. Coccaro EF, "Elevated plasma oxidative stress markers in individuals with intermittent explosive disorder and correlation with aggression in humans", Biol Psychiatry, 79, pp.127~135 (2016)
31. D’Souza B, "Oxidative injury and antıoxidant vitamins E and C in schizophrenia", Indian J Clin Biochem, 18, pp.87~90 (2003)
32. Kamal NAM, "Oxidative stress biomarkers in bipolar disorder with suicidal behavior : a systematic review", J Pharm Negat Results, 10, pp.6~15 (2019)
33. Zincir SB, "Role of Asymmetric Dimethylarginine in Psychiatric Disorders", Curr Approaches Psychiatry, 6, pp.355~362 (2014)

관련 논문AI추천